Carisma Therapeutics has gone public, entered a broad collaboration with Moderna, and ceased development of its original ...

We live in a time of hope for millions around the world, as technological advancements and research breakthroughs hold the ...

Effective provider segmentation can make or break a new drug launch, and can also improve the lifecycle of existing portfolio ...

Configurable FlexFactory™ biomanufacturing process trains can help scientists better control the production and processing of different viral vectors and new modalities—all within the same space. Plan ...

The brain cancer therapy recently approved by the FDA, Voranigo (vorasidenib), was developed from research by Duke University’s Darell Bigner and Johns Hopkins University's Bert Vogelstein and ...

In the 1980s, North Carolina emerged as a hub for biotechnology, largely due to the establishment of the North Carolina Biotechnology Center (NCBiotech). A state-supported, accelerator-style entity, ...

E. Magnus Ohman, vice president of global development, general medicine, Amgen, reflects on the remarkable evolution of North Carolina's biotechnology sector, tracing its growth from humble origins to ...

Biopharmaceutical companies must address the frictions and challenges that have quietly infiltrated the drug development ...

Conventional process liquid and buffer manufacturing is resource-intensive, requiring a significant facility footprint and high costs associated with labor, particularly as biologic drug production ...